Tag: MRNA
CureVac is an Underappreciated Opportunity, Says UBS
Investors may want to keep an eye on CureVac (CVAC).
After pulling back from about $12.50 to $10.50, CVAC could see higher highs. In fact,...
The Top 3 Vaccine Trades that Should be in All Portfolios
Moderna (MRNA) has been incredibly explosive for us.
The first time we highlighted opportunity, the stock traded at $72 on Oct. 20. At the moment,...
This is Why Moderna Could Run to $200, Near-Term
Vaccine news has created big opportunity.
Look at BioNTech for example. The stock exploded from $88.50 to $124.24 after it and Pifzer said its vaccine had...
Moderna Inc. Could Have Vaccine by December 2020
Keep an eye on Moderna Inc. (MRNA).
The COVID-19 vaccine stock is regaining some lost ground. All after CEO Stephane Bancel said the U.S. government...
Popular Post
